Literature DB >> 30502252

SIRT3 Inactivation Promotes Acute Kidney Injury Through Elevated Acetylation of SOD2 and p53.

Jie Ouyang1, Zhenhua Zeng2, Haihong Fang3, Fei Li1, Xinji Zhang1, Wanlong Tan4.   

Abstract

BACKGROUND: The deactivation of SIRT3, a novel deacetylase located in mitochondria, can aggravate multiple organ dysfunction. However, the role of SIRT3 and its downstream targets in ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) remain unknown.
MATERIALS AND METHODS: I/R was reproduced in a rat model using a clamp placed on the left and right renal pedicles for 40 min. The rats were intraperitoneally injected with either the vehicle or a selective SIRT3 inhibitor (3-TYP) and scarified at different time points (4, 8, and 24 h after I/R). A portion of the renal tissue was extracted for histological analysis, and another portion was collected for the isolation of renal tubular epithelial cells for Western blotting, SOD2 and SIRT3 activity, cell apoptosis, and the determination of oxidative stress.
RESULTS: The I/R-induced AKI model was successfully reproduced and SIRT3 activity was considerably reduced than control (sham operated) group, accompanied by increased acetylation of SOD2 and p53, as well as their elevated physical interaction in extracted mitochondrial protein (all P values < 0.05). Moreover, SIRT3 suppression by 3-TYP treatment (comparing with the vehicle treatment group) aggravated AKI, as evidenced by increased indicators of oxidative stress (increased mitochondrial red fluorescence MitoSOX and decreased reduced glutathione/oxidized glutathione ratio, all P values < 0.01).
CONCLUSIONS: The elevation of SOD2 and p53 protein acetylation in the mitochondria of renal tubular epithelial cells is an important signaling event in the pathogenesis of I/R-induced AKI. Thus, deacetylase SIRT3 may be an upstream regulator of both SOD2 and p53, and the SIRT3 deactivation may aggravate AKI.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute kidney injury; Deacetylation; Ischemia/reperfusion; SIRT3; SOD2; p53

Mesh:

Substances:

Year:  2018        PMID: 30502252     DOI: 10.1016/j.jss.2018.07.019

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

1.  Network Pharmacology-Based Exploration of the Therapeutic Mechanisms of Cordyceps cicadae in Renal Ischemia/Reperfusion.

Authors:  Jiajun Dong; Mingyang Cao; Hui Yu; Yang Dong; Conghui Han
Journal:  Ann Transplant       Date:  2022-09-30       Impact factor: 1.479

2.  Sirtuin 3 Alleviates Diabetic Cardiomyopathy by Regulating TIGAR and Cardiomyocyte Metabolism.

Authors:  Lanfang Li; Heng Zeng; Xiaochen He; Jian-Xiong Chen
Journal:  J Am Heart Assoc       Date:  2021-02-15       Impact factor: 5.501

Review 3.  Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target.

Authors:  Jin Zhang; Honggang Xiang; Jie Liu; Yi Chen; Rong-Rong He; Bo Liu
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

4.  Estrogen and estrogen receptors in kidney diseases.

Authors:  Hao-Yang Ma; Shuang Chen; Yang Du
Journal:  Ren Fail       Date:  2021-01-01       Impact factor: 2.606

5.  Cytoplasmic sirtuin 6 translocation mediated by p62 polyubiquitination plays a critical role in cadmium-induced kidney toxicity.

Authors:  Keum-Young So; Byung-Hyun Park; Seon-Hee Oh
Journal:  Cell Biol Toxicol       Date:  2020-05-11       Impact factor: 6.691

Review 6.  The Role and Mechanism of Histone Deacetylases in Acute Kidney Injury.

Authors:  Xun Zhou; Hui Chen; Yingfeng Shi; Xiaoyan Ma; Shougang Zhuang; Na Liu
Journal:  Front Pharmacol       Date:  2021-06-16       Impact factor: 5.810

7.  Sirt3 modulates fatty acid oxidation and attenuates cisplatin-induced AKI in mice.

Authors:  Ming Li; Can-Ming Li; Zeng-Chun Ye; Jiayan Huang; Yin Li; Weiyan Lai; Hui Peng; Tan-Qi Lou
Journal:  J Cell Mol Med       Date:  2020-04-12       Impact factor: 5.310

8.  SIRT3 Regulation of Mitochondrial Quality Control in Neurodegenerative Diseases.

Authors:  Hao Meng; Wan-Yu Yan; Yu-Hong Lei; Zheng Wan; Ye-Ye Hou; Lian-Kun Sun; Jue-Pu Zhou
Journal:  Front Aging Neurosci       Date:  2019-11-12       Impact factor: 5.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.